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Abstract:  Post-polio  syndrome  (PPS)  refers  to  the  clinical  deterioration  experienced  by 
many polio survivors several decades after their acute illness. The symptoms are new muscle 
weakness, decreased muscle endurance, fatigue, muscle pain, joint pain, cold intolerance, and 
this typical clinical entity is reported from different parts of the world. The pathophysiology 
behind PPS is not fully understood, but a combination of distal degeneration of enlarged motor 
units caused by increased metabolic demands and the normal aging process, in addition to 
inflammatory mechanisms, are thought to be involved. There is no diagnostic test for PPS, and 
the diagnosis is based on a proper clinical workup where all other possible explanations for 
the new symptoms are ruled out. The basic principle of management of PPS lies in physical 
activity, individually tailored training programs, and lifestyle modification. Muscle weakness 
and muscle pain may be helped with specific training programs, in which training in warm 
water seems to be particularly helpful. Properly fitted orthoses can improve the biomechanical 
movement  pattern  and  be  energy-saving.  Fatigue  can  be  relieved  with  lifestyle  changes, 
assistive devices, and training programs. Respiratory insufficiency can be controlled with 
noninvasive respiratory aids including biphasic positive pressure ventilators. Pharmacologic 
agents like prednisone, amantadine, pyridostigmine, and coenzyme Q10 are of no benefit in 
PPS. Intravenous immunoglobulin (IVIG) has been tried in three studies, all having positive 
results. IVIG could probably be a therapeutic alternative, but the potential benefit is modest, 
and some important questions are still unanswered, in particular to which patients this treatment 
is useful, the dose, and the therapeutic interval.
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Introduction
Poliomyelitis (polio) occurs as a result of infection by the polio virus, which in 
1%–2% of infected patients attacks the anterior horn in the spinal cord, leading to 
inflammation and possible cell death. After the introduction of the polio vaccines in 
the 1950s, the polio epidemics diminished rapidly in the industrialized world, but 
there are still areas in Asia and Africa where the virus is endemic and epidemics occur. 
Acute polio is no longer a constant threat to people in the polio-free areas of the world 
(Europe, the US, and the Pacific), but there are still thousands of polio survivors who 
are at risk of developing late manifestations of the disease. Even though the first 
report of new muscle weakness following recovery from acute paralytic poliomyelitis 
was published in 1875,1 polio was long considered to be a three-phase illness, with 
muscle weakness followed by recovery, and then a life-long stable plateau phase. 
This paradigm was challenged when large groups of polio patients, who became ill Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Farbu
in the epidemics of the 1940s and 1950s, reported clinical 
deterioration and a new condition several years after the 
acute illness. The symptoms were common to different 
polio populations all over the world, and as the reports 
were systematically recorded, the term “post-polio 
syndrome” (PPS) were coined in the 1980s, describing 
this new, late manifestation of polio after several years 
with stable function following initial recovery.2 Public 
awareness of this topic seems to be increasing,3 and the 
term PPS is now widely accepted.
The exact prevalence of PPS among polio survivors is 
not known, but studies have reported a PSS prevalence in 
15%–80% of all patients with previous polio, depending on 
the criteria applied and population studied.4–10 The precise 
prevalence of PPS is therefore difficult to establish, and a 
genuine difference between different populations cannot be 
excluded. The prevalence in two US polio populations was 
28.5% and 64%, respectively.10,11 For European populations, 
one Dutch study reported a prevalence of late onset polio 
symptoms of 46%, one study from Edinburgh reported a 
prevalence of more than 60%, a prevalence of 52% has 
been reported in Estonia, with 60% for Norway, and 63% 
for Denmark.9,12–14
Clinical features and diagnosis
The major clinical features of PPS are new muscle weakness, 
new atrophy, muscle and joint pain, increased muscular 
fatigability, general fatigue, and cold intolerance.2,5,6,9,15,16 
The diagnostic process for PPS is concentrated on a thor-
ough clinical workup where all other possible neurologic, 
medical, orthopedic, and psychologic causes for the new 
deterioration are ruled out. There is no diagnostic test for 
PPS, and the diagnosis is based on clinical criteria. Several 
authors have proposed diagnostic criteria for PPS,5,16,17 
where the March of Dimes (MoD) criteria seem to be 
more and more universally accepted. The MoD criteria 
also include that symptoms should persist for at least one 
year, illustrating the chronic course. The MoD criteria are 
as follows:
•	 Prior paralytic poliomyelitis with evidence of motor 
neuron loss, as confirmed by a history of the acute 
paralytic illness, signs of residual weakness, and atrophy 
of muscles on neurologic examination, and signs of 
denervation on electromyography.
•	 A period of partial or complete functional recovery 
after acute paralytic poliomyelitis, followed by an 
interval (usually 15 years or more) of stable neurologic 
function.
•	 Gradual or sudden onset of progressive and persistent 
muscle weakness or abnormal muscle fatigability 
(decreased endurance), with or without generalized 
fatigue, muscle atrophy, or muscle and joint pain. (Sudden 
onset may follow a period of inactivity, or trauma, or 
surgery). Less commonly, symptoms attributed to PPS 
include new problems with swallowing or breathing.
•	 Symptoms persisting for at least a year.
•	 Exclusion of other neurologic, medical, and orthopedic 
problems as causes of symptoms.
Widespread muscle weakness and female gender are 
considered to be the major risk factors for PPS.11 The new 
weakness or atrophy is usually asymmetric and limited 
to certain muscle groups, proximal or distal, either in 
previously weakened or presumably unaffected muscles. 
Electromyography may show subclinical involvement, 
with enlarged motor units in clinically unaffected muscles 
indicating a subclinical involvement during the acute illness. 
More than 50% of the motor neurons within one spinal 
cord segment must be destroyed before a weakness can be 
detected clinically.18 Ivanyi et al showed that a computed 
tomography (CT) scan of polio muscles may be helpful to 
explore the muscle abnormalities, and thereby supplying 
clinical and neurophysiologic examinations.19 Whether 
magnetic resonance imaging (MRI) can be helpful to detect 
anterior horn abnormalities in PPS remains to be investi-
gated in future studies. Decreased muscle endurance and 
increased muscle fatigue is common, and may precede the 
weakness. A subtle first sign may be that the time needed 
for recovery after muscle activity increases, and muscle 
endurance slowly deteriorates. Whether generalized fatigue 
is primarily physiologic or multifactorial is debated,20–22 
but it is important to bear in mind that this phenomenon 
is considered by many patients to be the most disabling 
symptom in their daily life.
Muscle pain is very common6 and appears to be due to 
overuse of weak muscles or disuse of other muscle groups 
compensating for weakened polio-affected muscles. Joint 
pain can be caused by joint instability, anisomelia (unequal 
length of limbs), disuse of muscles, abnormal biomechanical 
movements, and degenerative joint diseases. Scoliosis 
and kyphosis can lead to an unbalanced workload in the 
spine, leading to asymmetric degenerative changes and the 
risk of radiculopathies in the neck or lower back. Chest 
deformities also increase the risk of respiratory insufficiency, 
and excessive daytime sleepiness, sleep apnea, morning 
headache, and dyspnea are typical complaints from patients 
with polio-related respiratory problems. Bulbar muscles can Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
309
Treatment of post-polio syndrome
also be affected (causing dysphagia, obstructive sleep apnea, 
dysarthria, or facial weakness), but symptoms from this level 
are not common.6,23–26
Pathogenesis
There is a consensus that the neuromuscular symptoms 
of PPS can be explained by loss of enlarged motor units, 
which can be up to 10 times the normal size.27 There is an 
ongoing denervation and reinnervation, but the reinnervation 
process has an upper limit where the reinnervation cannot 
compensate for the ongoing denervation, and loss of 
motor units takes place.5,7,28,29 However, what disturbs the 
denervation-reinnervation equilibrium and causes peripheral 
denervation is still unclear. Different etiologies have been 
proposed, including persistence or reactivation of polio 
virus infection, normal aging process causing loss of motor 
neurons, increased metabolic demand in the motor neurons, 
inflammation at the spinal level, loss of muscle fibers or 
change in intrinsic properties within muscle fibers, and a 
combination of factors including overweight, disuse, overuse, 
and deconditioning.30–34
Research has not been able to verify a persistent polio 
virus infection or relation to PPS, and it seems unlikely that 
persistent poliovirus infection plays a role in the pathogenesis 
of PPS.35–37
When it comes to noninfectious inflammation at the 
spinal level, there are several observations that support 
this hypothesis, ie, perivascular inflammatory signs in the 
spinal cord with mononuclear cells, antibody responses 
in the cerebrospinal fluid (CSF), and increased levels 
of inflammatory cytokines in the CSF.33,38,39 A systemic 
inflammatory response has also been postulated.32,40 At this 
time, there seems to be robust evidence that inflammatory 
changes at the spinal cord level play a significant role in the 
pathogenesis, and they may serve as a target for therapeutic 
approaches.33,41–43
After the third decade, all healthy individuals lose both 
numbers of motor units and a degree of muscle strength as 
a part of the normal aging process. This will also occur for 
PPS patients, but they have a greater loss of both strength and 
motor units,27 and the clinical consequences may be greater 
than in healthy humans because more muscle fibers are 
denervated within one enlarged motor unit.27,34 The normal 
ageing process probably contributes to the loss of muscle 
strength, but does not explain all of the deterioration. In 
previously polio-affected muscles, Type 1 fibers dominate, 
and there is decreased capillary density and reduced oxidative 
capacity.44
Treatment options
Nonpharmacologic treatment
The management of PPS is still based on rehabilitation 
schemes including lifestyle changes, physiotherapy, training 
programs, and avoidance of secondary complications.25,45 
An important advance occurred when it was documented 
that nonfatiguing exercises improved muscle strength and 
prohibited further decline of PPS without any obvious 
harmful effects. Several clinical aspects can be modulated 
with physical activity, including generalized fatigue, 
improved muscle endurance, and muscle strength, and were 
identified after introduction of individually tailored training 
programs. There are multiple ways of performing physical 
activity, and isokinetic, isometric, and endurance muscle 
training are all effective, leading to less fatigue and improved 
muscle strength.46–51 No complications or side effects were 
reported in these studies, but emphasis on avoiding overuse, 
as well as intermittent workouts with sufficient rest between 
interval exercises has been mandatory. Training on alternate 
days to allow enough recovery and nonfatiguing exercises 
with short duration and submaximal workload are methods 
to avoid overuse and decline in muscle function.25 Because 
several training methods are effective, there should be good 
opportunities for individually tailored patient programs, 
where the pattern of muscle weakness and general health 
status are taken into account when adjusting the program. 
Until now, there have been no long-term studies exploring 
the effects of training, except for two open follow-up studies 
where a positive effect on fatigue and physical capacity was 
found up to one year after the intervention.52,53 It seems that 
training programs performed in a warm climate can result 
in a longer lasting effect compared with training schemes 
in a colder climate,54 but studies investigating the potential 
long-term benefits have not been reported.
Training in warm water reduces the stress on joints and 
muscles, and warm water may have an analgesic effect. 
Dynamic water exercises, not involving swimming, are a 
good alternative for patients with PPS, with positive effects 
on pain relief, improved cardiovascular conditioning, and 
increased subjective well-being.55
Weakening of bulbar muscles causing dysphagia, 
weakness of voice, and vocal changes have been reported 
among PPS patients,24,56–58 but bulbar symptoms are not 
among the most frequent features. Speech therapy and 
laryngeal muscle training under supervision by speech 
therapists are useful to improve bulbar muscle function.56
The risk of respiratory insufficiency should be considered, 
because it could lead to serious complications, including Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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increased frequency of respiratory infections, hypercapnia, 
pulmonary arterial hypertension, and ultimately, cor pul-
monale. For PPS patients, weakened respiratory muscles in 
addition to severe chest deformities, such as kyphoscoliosis, 
can cause respiratory insufficiency. Typical symptoms are 
daytime sleepiness, sleep apnea, morning headache, and 
dyspnea. Early introduction of noninvasive respiratory aids 
such as intermittent positive pressure ventilation or biphasic 
positive pressure ventilators via a mouthpiece or nasal appli-
cation can stabilize the situation and prevent complications 
like chest infections, further respiratory decline, and invasive 
ventilatory aid (with tracheostoma),59,60 and can also improve 
exercise capacity.45,61 Today’s ventilators are handy in size and 
user-friendly, which increases compliance. PPS patients with 
a tracheostoma and mechanical home ventilation are reported 
to have good quality of life despite severe physical disability.62 
In line with other muscle training in PPS, respiratory muscle 
training is useful, including for patients already using an 
intermittent noninvasive respiratory aid.63 General measures 
like stopping smoking, mobilization of secretions, and cough 
assistance are beneficial, and should be followed in all cases 
with PPS-related respiratory insufficiency.45,60
A shift from metal braces to lightweight carbon orthoses 
can increase walking ability in polio patients with new 
weakness,45,64–66 and biomechanical analysis of the walking 
pattern can lead to optimal design of orthoses and improved 
function in the lower limbs.45,65,67
Frequent periods of rest, energy conservation, and work 
simplification skills are thought to be useful for patients with 
fatigue,68 and general lifestyle modifications including weight 
control, physical activity, adaptation to assistive devices, 
and modification of daily activities are always advocated to 
diminish the symptoms of fatigue.
Pharmacologic agents available
The findings of inflammatory markers in the serum and CSF 
from PPS patients have raised the questions of the degree to 
which inflammation is a part of the pathophysiology and if 
there could be a benefit from anti-inflammatory treatment. 
This issue was partly explored in the 1990s, when prednisone 
was tried in combination with amantadine. No positive effect 
on muscle strength and fatigue was detected.69,70 However, 
these trials included small numbers of patients, and only one 
was designed to include a statistical power analysis. Because 
long-term use of steroids is connected with unwanted side 
effects, including increased risk of diabetes, osteoporosis, 
and steroid-induced myopathy, other pharmacologic agents 
should probably be tried first in PPS, given that is is a chronic 
disorder.
Pyridostigmine has been investigated in two randomized 
controlled studies, but was found to be without benefit 
regarding fatigue, quality of life, and muscle strength.71,72 
The same lack of benefit on fatigue was reported when 
modafinil (400 mg daily) was investigated in a controlled 
study, and was found to be no better than placebo.73 Lam-
otrigine has been tried in an open study (15 patients treated 
with 50–100 mg lamotrigine daily), where a positive effect 
on quality of life (Nottingham Health Profile), pain (visual 
analog scale), and fatigue (fatigue severity scale) was 
found after two and four weeks.74 Because this study was 
single-blinded and not placebo-controlled, a randomized 
controlled trial is needed to confirm the results. A small 
double-blind pilot study did not find any additional positive 
effect on muscle resistance training for patients taking 200 
mg coenzyme Q10 daily.75
Intravenous immunoglobulin
Despite the increasing use of intravenous immunoglobulin 
(IVIG) in neurologic autoimmune disorders over the past 
three decades, the mechanisms for the clinical effects of this 
therapy are not well understood. IVIG is thought to have the 
potential to act via several mechanisms, including effects 
on expression and function of Fc-receptors, modulation of 
the activation and effector functions of B- and T-cells, the 
complement system, neutralization of pathogenic antibodies, 
and cytokine production.76
Gonzales et al were the first researchers to show that IVIG 
reduced CSF inflammatory cytokine levels in PPS patients,41 
and this observation provided the rationale for trying IVIG 
as a therapy in PPS. IVIG is considered to have a more 
favorable side effect profile than long-term corticosteroids. 
Adverse reactions from IVIG are rare but severe, and include 
thromboembolic events (stroke, myocardial infarction, 
pulmonary embolism), particularly in patients with a 
pre-existing increased risk for thromboembolic disease, 
eg, diabetes and established arteriosclerosis.77 Patients with 
pre-existing renal disease are at risk of reversible renal tubular 
necrosis, and in patients with severe IgA deficiency there 
is an increased risk of anaphylaxis.78 More common, but 
self-limiting, mild reactions include infusion-related head-
ache, chills, muscle pain, and low back pain, and these infu-
sion-related reactions can sometimes be relieved by slowing 
the infusion rate.78 Despite the potentially serious side effects, 
occurring particularly in predisposed patients, IVIG is gener-Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ally considered to be a safe and effective first-line therapy 
for several autoimmune neurologic diseases, including Guil-
lain Barré syndrome, chronic inflammatory demyelinating 
polyneuropathy, and exacerbations of myasthenia gravis. For 
patients with PPS, three studies have explored the effects 
of IVIG, comprising two controlled studies and one open 
study. A multicenter double-blind, randomized Swedish study 
included 135 patients in whom the primary endpoints were 
muscle strength in a pre-selected muscle group and quality of 
life (SF-36 scale). The patients were treated with either IVIG 
90 g or placebo, repeated after three months. A significant 
difference on muscle strength was found, but there was no 
significant effect on quality of life or the secondary endpoints 
of pain, balance, and sleep quality.43
One smaller, randomized, controlled pilot study was 
performed in 20 patients by Farbu et al.79 The primary 
endpoints were muscle strength (isometric), pain (visual 
analog scale), and fatigue (fatigue severity scale) after 
three months. The patients were treated with one dose of 
IVIG (2 g/kg body weight). A significant effect was found 
for pain, but not for muscle strength or fatigue. It was also 
found that the levels of the inflammatory cytokine, tumor 
necrosis factor, in the CSF were reduced after treatment. 
A further open study done in 14 patients explored the effect 
of 90 mg IVIG on muscle strength, physical ability mea-
sured by a walking test, and quality of life (SF-36).80 There 
was a positive effect on quality of life, but not on muscle 
strength or physical ability. These studies give a promising 
indication that IVIG probably is a treatment option to some 
patients with PPS, but it is not clear which patients would 
benefit from this therapy. The existing studies should be 
interpreted according to their methodologic limitations, in 
that they have not explored the long-term effects, optimal 
dose, or optimal therapy cycle, and the modest observed 
benefits. The use of IVIG in various neurologic disorders 
is expanding, but it has limited availability and comes at a 
very high cost. This calls for more investigation of PPS, to 
help distinguish between responders and nonresponders, 
long-term effects, dose, and treatment interval. A cost–
benefit analysis should also be performed. Gonzales et al 
recently published a paper where five possible proteins 
are suggested to be predictable biomarkers for PPS, ie, 
gelsolin, hemopexin, peptidylglycine alpha-amidating 
monooxygenase, glutathione synthetase, and kallikrein 6.42 
These observations are important, and could lead to a new 
approach when confirming the diagnosis and developing 
new therapeutic strategies.
Conclusion
The primary treatment of PPS today is based on non-
pharmacologic intervention, including individually tailored 
training programs and lifestyle modification. Prednisone, 
amantadine, pyridostigmine, and modafinil are of no benefit 
for these patients. However, novel research during the last 
decade has uncovered changes in the CSF which probably 
play a role in the pathogenesis. These changes can be targets 
for anti-inflammatory treatments, and IVIG has been tried 
with promising, albeit modest results. Before IVIG can be 
recommended as standard therapy, we need to undertake more 
research to detect the long-term effects of this treatment, 
and to identify patients who will benefit from the treatment 
(responders versus nonresponders), and we need to find the 
appropriate dose and proper treatment interval.
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